Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients.
Main objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy.
Secondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy.
Exploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.
Patients who underwent pancreatic surgery, including pancreaticoduodenectomy (PD), pancreatic-preserving pancreaticoduodenectomy (PPPD), and laparoscopic pancreaticoduodenectomy (LPD)
Age ≥ 18 years old and < 80 years old
ASA Ⅰ-Ⅲ
Be able to clearly understand and voluntarily participate in the research
Merging severe primary diseases involving the heart, brain, liver, kidneys and hematopoietic system
History of long-term use of psychotropic drugs and cognitive dysfunction
Having a history of acute poisoning from alcohol, sleeping pills, painkillers or other drugs that affect the central nervous system
Pregnancy or lactation period